Andelyn Biosciences, Inc., a cell and gene therapy CDMO, has been selected by Ultragenyx to perform late-stage Process Performance Qualification (PPQ) manufacturing of the company’s UX111 gene therapy for the potential treatment of Sanfilippo Syndrome (MPS IIIA). MPS IIIA is derived from a sulfamidase enzyme deficiency responsible for abnormal accumulation of glycosaminoglycans in the brain and throughout the body leading to progressive cell damage and neurodevelopmental and physical de...